iPSC-Derived MSC Precursor Cells for High-Yield Exosome Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mesenchymal stem cells face limitations in functionality and proliferative capacity, particularly when used for exosome production, necessitating the development of cells with equivalent or superior properties.
Innovation Solution
Development of precursor cells derived from induced pluripotent stem cells (iPSCs), named Brexogen stem cells (BxC), which exhibit enhanced functionality and proliferative capacity, characterized by specific surface markers and gene expression profiles, and are produced through a method involving SSEA-4 negative selection and culture in bFGF-containing medium.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional mesenchymal stem cells are used for exosome production, then therapeutic effects can be achieved, but the amount of exosomes obtained is very small and the functions and proliferative capacity decrease with repeated passages
Solution Approach 1:
The patent changes the cellular state parameter by transitioning from differentiated mesenchymal stem cells to undifferentiated iPSCs, which fundamentally alters the proliferative capacity and exosome production potential. This parameter change resolves the contradiction by providing a cell source with both high proliferative capacity and high exosome yield.
Solution Approach 2:
The patent performs preliminary differentiation of iPSCs into mesenchymal lineage cells before exosome production. This preliminary action creates a cell population that retains the high proliferative capacity of stem cells while acquiring the functional characteristics needed for therapeutic exosome production, thereby resolving the contradiction between quantity and reliability.
2Productivity
If mesenchymal stem cells are repeatedly passaged for commercial use, then large amounts of cells can be obtained, but the functions and proliferative capacity of the stem cells decrease
Solution Approach 1:
The patent extracts the essential functional characteristics of mesenchymal stem cells (mesenchymal marker expression and exosome production capability) from the limitations of differentiated cells by using iPSCs as the starting material. This allows continuous production without the functional decline seen in traditional MSC passaging.
Solution Approach 2:
The patent creates a universal cell platform (iPSC-derived mesenchymal cells) that can serve multiple purposes: maintaining high proliferative capacity for large-scale production, expressing mesenchymal markers for functional equivalence, and producing therapeutic exosomes. This multi-functionality resolves the contradiction between productivity and reliability.
3Reliability
If differentiated mesenchymal stem cells are used, then therapeutic functions are achieved, but the proliferative capacity is limited compared to undifferentiated stem cells
Solution Approach 1:
The patent introduces dynamic control of cell differentiation state. The iPSC-derived mesenchymal cells can be maintained in an undifferentiated state for proliferation, then differentiated when needed for therapeutic function, and re-differentiated subsequently. This dynamic state change resolves the contradiction between therapeutic reliability and proliferative productivity.
Data Source
AI summary
The present disclosure relates to precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and a preparation method therefor. The precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells of the present disclosure have enhanced functionality and excellent proliferative capacity compared with typical mesenchymal stem cells or induced pluripotent stem cell-derived mesenchymal stem cells.